Member Info for dallo

Islandgirl

To correct my statement that Public companies cannot say they are in advanced discussions , I meant that a definitive statement like this would suggest an imminent transaction was around the corner.

As a Director of a number of Public Companies , I would never sign off on such a declaration unless it was almost in the bag.

Cheers

Islandgirl

No public company can say it is advanced discussions but Immupharma has implied that such discussions have been accelerated since the recent RNS and the US conferences.

Read between the lines..that's all I can say.

ATB

Remember if a big Pharma launches a takeover ,the value of Immupharma's deferred tax losses of c £60m are worth c £12m leaving its groundbreaking P140 drug therapies and diagnostics at a value of just £15m.

The RNS was a regulatory Stock Exchange requirement because of the surge in the SP from a derisory 1.2p and the Directors are now protected from accusations of insider trading so the Nomad and the company are now saying let the market decide on a correct price for the shares in the light of the recent extraordinary newsflow.

If a major development happens in the next week/ month then the Directors are fine having said that the company is in advanced discussions on potential commercial/ partnership deals.

Until a deal is signed, sealed and delivered then the company cannot say much more.

ATB

Rock

100% agree

Adding substantial amounts today and yesterday.

ATB

Under Stock Exchange regulations for UK listed companies, the Directors must issue an explanatory RNS where there are extraordinary movements in the company's share price particularly to cover themselves under Insider Trading Rules .

The company has confirmed the public information released in its recent RNS and the CEO's interviews.

However that does not prelude the future disclosure of commercial/ partnership deals even if such deals are currently being finalised.

So no real change or adverse information in the RNS and the Directors can now sleep easy.

ATB

Nolupus

Cracking good attempt at a clear round but 4 faults for not being able to spell theirs.

AI will sort you out ..it is more intelligent than the mortals on this board.

Don't worry I am beginning to lose the plot myself at 72.

ATB

Nolupus

Loose their memories or lose their memories

Oh dear

Call your GP

Nolupus

That post must have taken some time..no jumbled up spoonerisms .

Just for once in 8 years would you not be happy for the long suffering longtermers who may finally see some returns on their investment.

Forget about the newbies Tik Tokers but "your mates" on this board.

It has been a long journey but some of us are still here out of stubbornness and possibly madness.

ATB

Nolupus

Is that lose their shirts or shorts.

Your spelling and composition has gone to the dogs over the past year.

Hope you are OK.

Anyway why do you bother when you never invested in Immupharma.

You are becoming a little sad even when us longtermers are having a bit of joy.

Strange

Nolupus

Investors have to play with their own cards.

I advised Cauldstream to top slice if he is in profit so that applies to us all.

ATB

For those newbies who don't understand the Lanstead Agreement the base SP is 2.6p so when the SP is below 2.6p Lanstead pays a monthly payment based on the % below the 2.6p denominator and base monthly payment of £44,000.

However if the SP is above the denominator SP of 2.6p the payments increase exponentially.

Example at the current SP of 5.5p the monthly payments rise to £90,000 .

At say 8p the monthly payments rise to c £130,000 per month.

If the SP goes to say 13p the monthly payments go to

C £240,000 until the end of August 2025.

The share price has to stay above 4p for 5 consecutive business days for the 2p warrants to be exercisable.

So even if Lanstead and Alora exercise at 2p and the SP is say 8p Lanstead will do well but will be paying

Immupharma 8 months × £130,000 = c1.04m plus the the payment for the warrants of £1,4m totalling £2.44m.

Funding issue sorted

I picked up another 17,000 at 143.4p

Hard to get stock at the moment for some reason.

Peter

Agreed

But if don't believe in the groundbreaking RNS and McCarthy's interviews then you are correct to be concerned about Lanstead.

The coming weeks will illuminate the discussions .

You pays your money and take your chances.

If you don't believe sell asap, if you do stay invested.

Very simple really imho

Peter

If you understand the stock market, dumping large amounts of shares into a illiquid market is madness.

Selling into a rising liquid market is much easier.

Lanstead would shoot themselves in the foot if they dumped shares when there was no liquidity.

So liquidity and a rising share will facilitate trades and bring in new investors maybe some of who will be large strategic investors.

That's the way it works so if Immupharma languishes back at say 2p then liquidity dries up and trades are non existent so Lanstead are stuck like the rest of us

The next few weeks are going to tell a tale.

Enjoy the ride.

Peter

Also if Lanstead take up the warrants it has to pay £1.4m plus substantial additional monthly payments if the SP continues to rise so good for Immupharma's funding

ATB

Peter

If momentum continues Lanstead should be washed out very quickly..

Remember we needed Lanstead in the dark days so good luck to them.

I am more interested in our partner Alora Pharmaceuticals taking up its 23 m warrants to add to its c10m shares giving it total shares of 33m shares.

Peter

The original Phase 3 trial was funded by Immupharma and badly constructed with little work done on patient types and biomarker identification.

Lupus sufferers with positive Antibody biomarkers (60% of all the Lupus patients ) showed positive results but the cohort trialled was only identified in later analysis.

The new formulations and dosages ( 15/20 times the original dosages) and the precise identification of the clinical and pharmacology biomarkers of classification of patients is the new scientific development hence why the new trials have taken longer to commence. An enormous amount of work has gone into this over the past 12 months and allied to the groundbreaking developments announced recently made the prospects of successful commercialisation of the P140

Autoimmune therapies including Lupus, CIPD et al more probable.

The new patient Autoimmune diagnostic and disease identification revelations add to the excitement imho.

This week could be interesting but do you own research.

ATB

Remember even if the SP soars tomorrow it has to stay above 4p for 5 consecutive business days before the warrant holders primarily Lanstead ( 70m) and the Alora Pharma Group ( 23m) have the right not the obligation to exercise the warrants.

So far Lanstead appear not to have sold any of its 25 m shares ( c6.3%) so maybe it is impressed with the latest developments and are staying in.

Lanstead still have to pay a minimum monthly £44,000

to Immupharma at a base SP of c2.6p rising substantially as the SP rises above this denominator.

So in the extremely unlikely event of Lanstead and Alora not exercising the warrants should the SP soar

then it would be bizarre imho.

Let's see what this week brings.

ATB

The other big problem is that most of the big Institutional investors have invested in Puretech for many years and have seen no returns.

Daphne Zohar was pushed sideways into Seaport and rather than appoint a dynamic outsider, the Board appointed a boring accountant insider as CEO .

The market was not impressed hence I feel there is shareholder pressure to sell the company as evidenced by the large number of shareholders who applied for the Tender Offer at £2.50.

Bristol Myers may pounce to grab the cash and the Puretech royalties from Cobenfy plus the other assets.

Poor share price performance is not tolerated for long imho.

Fair play to Tim McCarthy who has travelled to the US and given 2 interviews and hit the ground running in 2025 all the while suffering from a bad Respiratory virus for the past 3 weeks .

Almost Trumpian in his endeavours.